Aster Capital Management’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.03K Buy
+106
New +$6.18K ﹤0.01% 823
2026
Q2
– Sell
-37
Closed -$1.4K – 1151
2026
Q1
$1.4K Buy
+37
New +$2.01K ﹤0.01% 773
2025
Q4
– Sell
-1,252
Closed -$45.1K – 1338
2025
Q3
$45.1K Buy
+1,252
New +$41.5K 0.02% 516
2024
Q4
– Sell
-4,173
Closed -$477K – 1418
2024
Q3
$477K Buy
+4,173
New +$376K 0.1% 210

Other funds holding PCVX

Aster Capital Management's PCVX Position: Q3 2026 in Review

Aster Capital Management opened a new position in Vaxcyte (PCVX) in Q3 2026: 106 shares worth $6.03K. The stake represents ﹤0.01% of the portfolio and ranks #823 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in PCVX as recently as Q1 2026.

Aster Capital Management first reported a position in PCVX in Q3 2024 and has held it in 4 quarters since. The position peaked at $477K in Q3 2024. 356 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Aster Capital Management held 106 shares of Vaxcyte worth $6.03K as of Q3 2026.
  • Vaxcyte was a new Aster Capital Management position in Q3 2026.
  • Vaxcyte made up ﹤0.01% of Aster Capital Management's portfolio in Q3 2026, its #823 holding.
  • Aster Capital Management first reported a position in Vaxcyte in Q3 2024 and has held it in 4 quarters since.
  • Aster Capital Management's Vaxcyte position peaked at $477K in Q3 2024.
  • 356 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.